ArticleDiscover oncology2025
Machine learning-based identification of exosome-related biomarkers and drugs prediction in nasopharyngeal carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Exosomes in diabetic kidney disease: pathogenesis, biomarker discovery, and emerging therapeutics-a comprehensive systematic review.Renal failure · 2026Pooled it
- Article
- Extracellular Vesicles: A Multidimensional Role in the Occurrence and Development of Nasopharyngeal Carcinoma.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeExosomes are recognized as essential mediators in the intercellular communication between tumor cells, serving a pivotal function in tumor development. Nevertheless, the patterns of expression and medical relevance of exosome-related genes (ERGs) in nasopharyngeal carcinoma (NPC) remain insufficiently characterized.
methodsDatasets retrieved from the Gene Expression Omnibus database were consolidated into a comprehensive gene dataset, which was then employed to ascertain differentially expressed genes (DEGs) by comparing NPC samples with controls. ERGs were intersected with the DEGs, yielding the detection of exosome-related DEGs. These identified genes underwent functional annotation and pathway enrichment evaluation. The least absolute shrinkage and selection operator regression, support vector machine, and random forest approaches were utilized to develop NPC diagnostic model. Key genes were determined through intersection analysis and subsequently confirmed in an independent cohort. Furthermore, drug screening, molecular docking, and molecular dynamics simulation were executed to generate meaningful insights for developing therapeutic compounds.
resultsThrough the application of three machine learning algorithms, five key genes (LTF, IDH1, ITGAV, CCL2, and LGALS3BP) were identified for the construction of a diagnostic model. Validation results demonstrated the strong discriminative and calibration abilities of the model. Furthermore, molecular docking analysis revealed that the interaction between IDH1 and nelfinavir exhibited the lowest Vina score, suggesting a stable binding affinity.
conclusionThis study identifies five exosome-related key genes, utilizing machine learning approaches to develop a diagnostic model and uncover potential drug targets for NPC. These findings offer novel perspectives for both the diagnosis and therapeutic development of NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.